Aclaris Therapeutics, Inc. (ACRS) bonds
ACRSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/30138% above fair value
$3.38−0.23 (-6.24%)
Close on Nov 17, 2026Market cap $497.53MP/E –Yield –
Debt
Borrowings on the balance sheet, Jun 30, 2026
Aclaris Therapeutics reports no long-term debt line
Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.
Notes and loans outstanding
As tagged in Aclaris Therapeutics's 10-K for the period ended Oct 31, 2018
Aclaris Therapeutics's filings do not break debt down by note
The debt footnote in the annual report has no machine-readable detail for individual notes, so coupons and maturities cannot be listed.
Credit facilities
Revolving credit lines and other committed borrowing capacity
| Facility | Size |
|---|---|
| Term Loan Facility | $65.00M |
See a number that looks wrong?